Coronavirus Update

The U.S. biopharmaceutical industry is working closely with U.S. government agencies, the World Health Organization and governments around the world to identify their most pressing needs in the areas of vaccination, diagnostics, and antivirals and other treatments, and to facilitate collaborations with industry.

To learn more about what the biopharmaceutical industry is doing to combat the virus and for a host of information and helpful resources (FAQ’s, CDC Information Hub, Safety Tips, etc.)
Slide One
Slide Two
Slide Three

Doctors Pier Claudio and Jagan Valluri have been working for years on a chemo sensitivity test, called ChemoID. They take a biopsy of a tumor, multiply the cancer stem cells, and find out what type of chemo that particular cancer will respond best to.

"I think you know the whole goal of cancer, is you know we want to cure it, but more importantly, how can we prolong the life of a cancer patient?" Valluri said.

Groundbreaking cancer research going on right here in Huntington could soon change the way patients are treated. 

"This is definitely a cutting edge technology for the 21st century for cancer patients," said Dr. Pier Paolo Claudio, a biomedical sciences researcher and professor at Marshall University's Joan C. Edwards School of Medicine. 


The 3rd Annual West Virginia Bioscience Summit, with sponsorship from BIO, PhRMA, Mylan, Amgen, Pfizer, the Blanchette Rockefeller Neuroscience Institute, the WV Small Business Development Center, Steptoe & Johnson PLLC, Fisher Scientific and TechConnect West Virginia, was held February 27-28, 2013 at the Charleston Marriott in Charleston, West Virginia.
This unique event drew together the region’s bioscience industry, to include university researchers, biotechnology company representatives, economic developers, funders, industry vendors, resource organizations and many others.  The Summit highlighted the role and impact of the bioscience industry in West Virginia and the region, showcased research and commercialization efforts taking place at West Virginia universities and private companies, and discussed policies and programs to help nurture the industry.
To review the event agenda, click here.
To review presentations offered during the event, click here.
To review a partial list of event attendees, click here.
To read media reports of the event from the Charleston Gazette click here, or for The State Journal, click here.
The dates for the 4th Annual WV Bioscience Summit – to be held winter 2014 – will be announced in the coming months.
For additional information, email This email address is being protected from spambots. You need JavaScript enabled to view it.

By Megan Workman
Charleston Gazette

CHARLESTON, W.Va. -- If David Scholl had given up on the Athens, Ohio-based startup biotech company that launched in the early 1980s, the company might not have sold for $130 million three years ago.

Scholl, the former president and chief executive officer of Diagnostic Hybrids Inc., spoke to a group of about 100 representatives from private companies, university researchers and biosciences suppliers and backers at the third annual West Virginia Biosciences Summit Thursday at the Charleston Marriott Town Center.

The State Journal

An array of speakers from a swath of academia and industry came together in Charleston talk about the burgeoning business of biosciences this week.

The Bioscience Association of West Virginia hosted the third annual Biosciences Summit to showcase research and commercialization efforts in state laboratories and boardrooms. The event highlights the industry efforts in the state, attracting state leaders such as Sens. Jay Rockefeller and Joe Manchin, and Gov. Earl Ray Tomblin.

PO BOX 20065 | Charleston, WV 25362 | (304) 546-5500